Author:
Nahta Rita,O’Regan Ruth M.
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95
2. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435–2446
3. Chang JCN, Forero-Torres A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC et al (2011) BCRC 006: a multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol 29(Suppl)(Abstract 505)
4. Gianni L, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch-Hernandez A et al (2010) Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’). Cancer Res 70(24S)(Abstract S3-2)
5. Guarneri V, Bottini A, Generali DG, Cagossi K, Artioli F, Bisagni G et al (2011) Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). J Clin Oncol 29(Suppl)(Abstract 507)
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献